CHMP recommends approval after KEYNOTE-B15 showed event-free survival, overall survival and pathologic complete response gains; European Commission decision expected Q4 2026.
Phase 3b data indicate a single Bexsero booster at age 10+ boosts immunity in those primed in infancy; full study results will be presented at IPNC in September.
EBITDA fell on weak silicon prices; raised NOK 1.8bn, refinanced EUR 1bn facility and obtained NOK 750m NIB loan; Elkem Iceland reclassified as discontinued.
EU selects fourth common auction platform for its emissions trading system; auctions begin 2027 and ETS2 auctioning starts January 2027 while ETS2 operations start in 2028.
Feasibility and financial modelling launched for a Kuopio flagship plant that aims to scale electro-based sustainable aviation fuel across the Nordics by 2040.
CHMP backed perioperative regimen for cisplatin‑ineligible resectable MIBC after Phase 3 KEYNOTE‑905 showed significant EFS, OS and pCR gains; EC decision due by Q3 2026; FDA cleared Nov 2025.
EBITDA fell 2.9% to €13.0m while sales dropped 12% to €221.0m; EBT improved on exchange-rate effects; Trading & Services and logistics strengthened; bond repaid €21.0m.
935 Nm3/h upgrading unit in a 45-ft container with SEPURAN Green membrane, ready to feed the gas grid by year-end; enables plant to raise output from 40 to up to 70 GWh/yr.
Strong Q1 driven by higher Nordic power prices despite lower hydropower output; underlying EBITDA NOK13.3bn, net profit NOK8.1bn, net debt down NOK8.3bn, ROACE 12.3%
Elkem introduces a new structure, reduces workforce by 300, and cuts costs by NOK 1.9 billion to enhance profitability amid market challenges.
active / all projects
